Neumora Therapeutics IPO Presentation Deck

Navacaprant Demonstrated Statistically Significant and Clinically Meaningful Improvements in Depression and Anhedonia Despite Inclusion of Mild Patients Change form baseline HAMD-17, LS Mean (SE) 0 -2 co -10 -12 Week 0 HAMD-17 Primary endpoint Week 4 -5.1 -7.9 ALSM = -2.7 P = 0.003 Week 8 -7.4 -9.0 ALSM = -1.7 P = 0.121 Improvement - Placebo Change form baseline SHAPS, LS Mean (SE) -Navacaprant 0 -2 + 6 CO -10 -12 Week 0 SHAPS Anhedonia scale Week 4 -3.7 -6.5 ALSM = -2.8 P = 0.004 Week 8 -4.4 -7.8 ALSM = -3.4 P = 0.002 Improvement Confidential 32

View entire presentation